BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-267@pharmaconomics
DTSTAMP:20260707T034253Z
DTSTART;VALUE=DATE:20260316
DTEND;VALUE=DATE:20260317
SUMMARY:RYTM Phase 2 — setmelanotide
DESCRIPTION:Phase 2 trial results for setmelanotide in acquired hypothalamic obesity are due Mar 16\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/q12026earningspr_draft.htm\n\nTrack it: https://www.pharmaconomics.com/e/267
URL:https://www.pharmaconomics.com/e/267
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RYTM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR